Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity

Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the persistence of the pandemic, even with mass coronavirus disease 2019 (COVID-19) vaccination, have raised questions about the durability of immunity and extent of cross-reactive immunity after vaccination. This study aimed to characterize the humoral and cellular immune response to the mRNA-1273 vaccine using a prospective longitudinal cohort. Methods We recruited 177 young SARS-CoV-2 infection-naive adults. Two doses of mRNA-1273 vaccine were administered at 28-day intervals, and blood samples were collected at five time points: pre-vaccination (T0), 4 weeks after the first (T1) and second dose (T2), and 3 months (T3) and 6 months (T4) after the first dose. Anti-SARS-CoV-2 spike protein (anti-S) IgG antibody, neutralizing antibody, and T-cell immune responses were evaluated. Results The two-dose mRNA-1273 vaccination induced robust anti-SARS-CoV-2 antibody responses, which remained higher than the titers at T1 until T4. A higher peak anti-S antibody titer at T2 was associated with better cross-reactive immunity against Delta and Omicron variants and long-lasting (anti-S IgG and neutralizing antibody) humoral immunity up to T4. The overall T-cell immune response was not correlated with peak antibody titers (T-lymphocyte subpopulation analysis was not performed). Conclusion This study showed that an early strong antibody response is predictive of longer humoral immunity and better cross-reactive neutralizing immunity against Delta and Omicron variants.

[1]  J. Sohn,et al.  Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study , 2023, Vaccines.

[2]  F. Cobo,et al.  Study of humoral and cellular immunity in vaccinated with mRNA‐1273 , 2022, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[3]  J. Qu,et al.  Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination , 2022, Cell discovery.

[4]  L. Poon,et al.  Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines , 2022, Research square.

[5]  D. Douek,et al.  mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant , 2022, Cell Reports Medicine.

[6]  Gheyath K Nasrallah,et al.  Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[7]  Gaurav D. Gaiha,et al.  Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines , 2021, The Journal of infectious diseases.

[8]  R. Baric,et al.  Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines , 2021, The New England journal of medicine.

[9]  Aaron M. Rosenfeld,et al.  mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern , 2021, Science.

[10]  Siti Norussaadah Mohd Salleh,et al.  Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians , 2021, The Lancet Regional Health - Western Pacific.

[11]  L. Suresh Six‐month longitudinal antibody kinetics of mRNA COVID‐19 vaccines , 2021, Rheumatology & autoimmunity.

[12]  L. Heylen,et al.  Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. , 2021, JAMA.

[13]  M. Vekemans,et al.  Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: A third dose is expected , 2021, Journal of Infection.

[14]  A. Mehta,et al.  Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells , 2021, Cell Reports Medicine.

[15]  A. Ellebedy,et al.  SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans , 2021, Nature.

[16]  A. Mehta,et al.  Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells , 2021, medRxiv.

[17]  J. Mascola,et al.  Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 , 2021, The New England journal of medicine.

[18]  E. Tejera,et al.  Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay , 2021, International Journal of Infectious Diseases.

[19]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[20]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[21]  Dong-Uk Park,et al.  Recommendation for the establishment of a poison control center at the Korea Disease Control and Prevention Agency , 2020, Environmental analysis, health and toxicology.

[22]  P. Kellam,et al.  Antibody response to SARS-CoV-2 infection in humans: A systematic review , 2020, medRxiv.

[23]  D. Weissman,et al.  A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice , 2020, Immunity.

[24]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[25]  Jason J. Lavinder,et al.  Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma , 2020, bioRxiv.

[26]  A. Handel,et al.  Heterogeneity and longevity of antibody memory to viruses and vaccines , 2018, PLoS biology.

[27]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[28]  R. Ahmed,et al.  Humoral immunity due to long-lived plasma cells. , 1998, Immunity.

[29]  F. Domínguez,et al.  Infective endocarditis in hypertrophic A multicenter , prospective , cohort study , 2016 .